[Pancreatic metastasis from undifferentiated pleomorphic sarcoma. An extremely rare entity]. / Metástasis pancreática de sarcoma pleomórfico indiferenciado. Una entidad extremadamente rara.

Undifferentiated pleomorphic sarcoma (UPS) is a very aggressive malignant tumor that originates in bone or soft tissues, being its most frequent location in the extremities. We present the case of a 71-year-old man who, two years of follow-up after a lower right limb UPS excision surgery, presented a single metastasis of sarcomatoid origin in the pancreas that was treated by cephalic pancreaticoduodenectomy. Sarcomatoid metastases to the pancreas are extremely rare. Resection of the metastasis is the only therapeutic alternative that has reported benefit in terms of the survival of these patients.

El sarcoma pleomórfico indiferenciado (SPI) es un tumor maligno muy agresivo que se origina en el hueso o tejidos blandos, siendo su localización más frecuente en las extremidades. Presentamos el caso de un varón de 71 años que a los dos años de seguimiento tras cirugía de exéresis de un SPI presenta una metástasis única de origen sarcomatoide a nivel del páncreas que se trató mediante duodenopancreatectomía cefálica. Las metástasis sarcomatoides a nivel de páncreas son extremadamente raras. La cirugía de exéresis de la metástasis es la única alternativa terapéutica que ha reportado beneficio en cuanto la supervivencia de estos pacientes.

Debut de enfermedad de Crohn durante tratamiento con ocrelizumab en paciente con esclerosis múltiple / Crohn's disease induced by ocrelizumab in a patient with multiple sclerosis

La enfermedad inflamatoria intestinal (EII) inducida por fármacos es una entidad clínica en aumento debido al uso frecuente de terapia inmunosupresora y biológica. Presentamos el caso de una paciente diagnosticada de enfermedad de Crohn durante el tratamiento con Ocrelizumab, anticuerpo monoclonal humanizado anti-CD20 aprobado para el tratamiento de la esclerosis múltiple. Se desconoce el mecanismo exacto por el que los fármacos inmunomoduladores pueden desencadenar EII, pero dado que la EII y la esclerosis múltiple son procesos incluidos dentro del espectro de enfermedades inmunomediadas, podríamos postular que el Ocrelizumab, al igual que otros anti-CD20 como el Rituximab o anti-TNF como Etanercept, pueda desencadenar o desenmascarar EII en pacientes genéticamente predispuestos. (AU)

Crohn's disease induced by ocrelizumab in a patient with multiple sclerosis.

Drug-induced inflammatory bowel disease (IBD) is a clinical entity on the rise due to the frequent use of immunomodulatory therapy. Here we report the case of Crohn's disease due to Ocrelizumab, a humanized anti-CD20 monoclonal antibody approved for the treatment of multiple sclerosis. The exact mechanism by which anti-CD20 antibodies can trigger IBD is unknown, but since IBD and multiple sclerosis are processes included within the spectrum of immunomediated diseases, we could suggest that Ocrelizumab could trigger IBD in genetically predisposed patients.

Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry.

Advanced gastric cancer is one of the most thrombogenic neoplasms. However, genetic mechanisms underlying this complication remain obscure, and the molecular and histological heterogeneity of this neoplasm hinder the identification of thrombotic biomarkers. Therefore, our main objective was to identify genes related to thrombosis regardless of Lauren subtypes. Furthermore, in a secondary exploratory study, we seek to discover thrombosis-associated genes that were specific to each TCGA molecular subtype. We designed a nested case-control study using the cohort of the AGAMENON national advanced gastric cancer registry. Ninety-seven patients were selected-48 with and 49 without venous thromboembolism (using propensity score matching to adjust for confounding factors)-and a differential gene expression array stratified by Lauren histopathological subtypes was carried out in primary tumor samples. For the secondary objective, the aforementioned differential expression analysis was conducted for each TCGA group. Fifteen genes were determined to be associated with thrombosis with the same expression trend in both the intestinal and diffuse subtypes. In thrombotic subjects, CRELD1, KCNH8, CRYGN, MAGEB16, SAA1, ARL11, CCDC169, TRMT61A, RIPPLY3 and PLA2G6 were underexpressed (adjusted-p < 0.05), while PRKD3, MIR5683, SDCBP, EPS8 and CDC45 were overexpressed (adjusted-p < 0.05), and correlated, by logistic regression, with lower or higher thrombotic risk, respectively, in the overall cohort. In each TCGA molecular subtype, we identified a series of genes differentially expressed in thrombosis that appear to be subtype-specific. We have identified several genes associated with venous thromboembolism in advanced gastric cancer that are common to Lauren intestinal and diffuse subtypes. Should these genetic factors be validated in the future, they could be complemented with existing clinical models to bolster the ability to predict thrombotic risk in individuals with advanced gastric adenocarcinoma.

Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.

BACKGROUND: Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical trials rarely include EAC. This work sought to compare clinical characteristics and treatment outcomes of advanced EAC with those of GEJ-AC and GAC and examine prognostic factors. PATIENTS AND METHODS: Participants comprised patients with advanced EAC, intestinal GEJ-AC, and GAC treated with platin and fluoropyrimidine (plus trastuzumab when HER2 status was positive). Overall and progression-free survival were estimated using the Kaplan-Meier method. Cox proportional hazards regression gauged the prognostic value of the AGAMENON model. RESULTS: Between 2008 and 2019, 971 participants from the AGAMENON-SEOM registry were recruited at 35 centers. The sample included 67.3% GAC, 13.3% GEJ-AC, and 19.4% EAC. Pulmonary metastases were most common in EAC and peritoneal metastases in GAC. Median PFS and OS were 7.7 (95% CI 7.3-8.0) and 13.9 months (12.9-14.7). There was no difference in PFS or OS between HER2- and HER2+ tumors from the three locations (p > 0.05). Five covariates were found to be prognostic for the entire sample: ECOG-PS, histological grade, number of metastatic sites, NLR, and HER2+ tumors treated with trastuzumab. In EAC, the same variables were prognostic except for grade. The favorable prognosis for HER2+ cancers treated with trastuzumab was homogenous for all three subgroups (p = 0.351) and, after adjusting for the remaining covariates, no evidence supported primary tumor localization as a prognostic factor (p = 0.331). CONCLUSION: Our study supports the hypothesis that EAC exhibits clinicopathological characteristics, prognostic factors, and treatment outcomes comparable to intestinal GEJ-AC and GAC.

[Subcutaneous infection by Curvularia pallescens in a lung transplant recipient: First report in Spain]. / Micosis cutánea por Curvularia pallescens en un paciente trasplantado pulmonar: primer caso descrito en España.

BACKGROUND: Curvularia is a filamentous dematiaceous fungus increasingly recognized as a pathogen in immunocompromised patients. The most common clinical entities associated with this fungus are allergic sinusitis, cutaneous infection and keratitis. In this article, a report on the first clinical case of Curvularia pallescens cutaneous infection in Spain and its treatment is described. CASE REPORT: A 68 year-old man with a history of lung transplantation presented to Dermatology Unit due to a skin lesion in the knee that had been evolving for 6 months. A skin biopsy was performed for its study. In the histopathological study, an intense and non-specific inflammatory reaction in the dermis was observed, and with Grocott stain and periodic acid Schiff abundant septate hyphae and spores were found in the dermis. The culture of the sample revealed a filamentous fungus whose microscopic examination allowed to identify the genus as Curvularia. Using MALDI-TOF mass spectrometry and molecular identification, the fungus was finally identified as Curvularia pallescens. The patient underwent surgical resection of the lesion and was treated with posaconazole, evolving favorably. CONCLUSIONS: The species of Curvularia should be considered causal agents of fungal skin infections in immunosuppressed patients. This clinical case, which showed good clinical response after surgical resection and treatment with posaconazole, is the first described in Spain due to this species.

Micosis cutánea por Curvularia pallescens en un paciente trasplantado pulmonar: primer caso descrito en España / Subcutaneous infection by Curvularia pallescens in a lung transplant recipient: first report in Spain

ANTECEDENTES: El género Curvularia incluye hongos filamentosos dematiáceos cada vez más reconocidos como patógenos en pacientes inmunocomprometidos. Las entidades clínicas más comunes con las que se asocia este hongo son la sinusitis alérgica, la infección cutánea y la queratitis. En este trabajo se describe el primer caso descrito en España de infección cutánea por Curvularia pallescens y su tratamiento. CASO CLÍNICO: Un varón de 68 años con antecedente de trasplante pulmonar acudió al servicio de dermatología por presentar una lesión cutánea en la rodilla de 6 meses de evolución. Se realizó una biopsia cutánea para estudio. La histopatología mostró una intensa reacción inflamatoria inespecífica en la dermis y mediante la tinción de Grocott y ácido peryódico de Schiff se observaron abundantes hifas septadas y esporas en la dermis. El cultivo de la muestra reveló un hongo filamentoso cuyo examen microscópico permitió identificar el género como Curvularia. Mediante espectrometría de masas MALDI-TOF e identificación molecular, el hongo finalmente se identificó como Curvularia pallescens. Se realizó resección quirúrgica de la lesión y el paciente recibió tratamiento con posaconazol, con resolución clínica de la lesión. CONCLUSIONES: El género Curvularia debe ser considerado un agente causal de micosis subcutáneas en pacientes inmunodeprimidos. Este caso clínico constituye el primero descrito en España producido por esta especie, el cual presentó buena respuesta clínica tras resección quirúrgica y tratamiento con posaconazol

BACKGROUND: Curvularia is a filamentous dematiaceous fungus increasingly recognized as a pathogen in immunocompromised patients. The most common clinical entities associated with this fungus are allergic sinusitis, cutaneous infection and keratitis. In this article, a report on the first clinical case of Curvularia pallescens cutaneous infection in Spain and its treatment is described. CASE REPORT: A 68 year-old man with a history of lung transplantation presented to Dermatology Unit due to a skin lesion in the knee that had been evolving for 6 months. A skin biopsy was performed for its study. In the histopathological study, an intense and non-specific inflammatory reaction in the dermis was observed, and with Grocott stain and periodic acid Schiff abundant septate hyphae and spores were found in the dermis. The culture of the sample revealed a filamentous fungus whose microscopic examination allowed to identify the genus as Curvularia. Using MALDI-TOF mass spectrometry and molecular identification, the fungus was finally identified as Curvularia pallescens. The patient underwent surgical resection of the lesion and was treated with posaconazole, evolving favorably. CONCLUSIONS: The species of Curvularia should be considered causal agents of fungal skin infections in immunosuppressed patients. This clinical case, which showed good clinical response after surgical resection and treatment with posaconazole, is the first described in Spain due to this species

Vasculitis leucocitoclástica tras la vacunación en una paciente con enfermedad inflamatoria intestinal / Leukocytoclastic vasculitis after vaccination in a patient with inflammatory bowel disease

Los pacientes con enfermedad inflamatoria intestinal son susceptibles de recibir tratamiento inmunomodulador y, por tanto, han de estar correctamente vacunados. Pese a la probada seguridad de las vacunas, estas no están exentas de reacciones adversas. A continuación, se presenta un caso clínico de una mujer joven con colitis ulcerosa en tratamiento con mesalazina que presentó vasculitis leucocitoclástica tras vacunación frente a neumococo, varicela y hepatitis A. Dicha reacción apenas está descrita en la literatura tras la administración de cualquiera de estas vacunas y nunca ha sido descrita en un paciente con patología de base

Patients with inflammatory bowel disease are likely to receive immunomodulation treatment and therefore, should be properly vaccinated. Despite their proven safety, vaccines are not exempt from adverse reactions. The clinical case was a young female with ulcerative colitis under mesalazine treatment, who developed leukocytoclastic vasculitis following vaccination for pneumococci, varicella and hepatitis A. This adverse reaction after the previously mentioned vaccines is barely described in the literature and has never been reported in a patient with an underlying condition

Leukocytoclastic vasculitis after vaccination in a patient with inflammatory bowel disease.

Patients with inflammatory bowel disease are likely to receive immunomodulation treatment and therefore, should be properly vaccinated. Despite their proven safety, vaccines are not exempt from adverse reactions. The clinical case was a young female with ulcerative colitis under mesalazine treatment, who developed leukocytoclastic vasculitis following vaccination for pneumococci, varicella and hepatitis A. This adverse reaction after the previously mentioned vaccines is barely described in the literature and has never been reported in a patient with an underlying condition.

Evaluación de la calidad del procedimiento de biopsia selectiva del ganglio centinela en pacientes con cáncer de mama, en un hospital comarcal / Assessment of the quality of selective sentinel lymph node biopsy in patients with breast cancer in a district hospital

Objetivo. Evaluar la calidad del procedimiento de la biopsia selectiva del ganglio centinela en la Unidad de Patología Mamaria de un hospital comarcal, sin servicio de Medicina Nuclear. Material y métodos. Se diseñó un estudio descriptivo, retrospectivo, en el que se incluyeron 104 pacientes con cáncer de mama no avanzado. El día previo a la cirugía se les realizó una linfogammagrafía en el hospital de referencia. Como instrumento de gestión, se empleó la guía clínica de autoevaluación de la Sociedad Española de Senología y Patología Mamaria. Estudiamos la eficacia en la detección del ganglio centinela, la sensibilidad y la media de ganglios centinelas axilares aislados por paciente. Se evaluaron tanto los resultados globales obtenidos por la Unidad de Mama, como los obtenidos individualmente por cada uno de los 3 cirujanos que la integran. Resultados. Se cumplieron los 3 criterios esenciales de la guía de autoevaluación, siendo: la detección del ganglio centinela del 94,2%, la sensibilidad acreditada del 93,2%, y la media de ganglios centinela axilares extraídos de 1,66 ± 0,84. Estos criterios también se cumplieron a nivel individual, por cada uno de los 3 cirujanos que integran la unidad. La aplicación de la guía de autoevaluación nos dio una puntuación global de 33 sobre 71 puntos, siendo el nivel de calidad ii el más prevalente. Conclusiones. En nuestra unidad, la aplicación de la guía publicada por la Sociedad Española de Senología y Patología Mamaria para evaluar los aspectos esenciales y básicos de la biopsia selectiva del ganglio centinela en cáncer de mama nos ha permitido confirmar que realizamos el procedimiento con suficiente garantía de calidad, y además, promover aspectos de mejora (AU)

Objective. To assess the quality of selective sentinel lymph node biopsy in the Breast Diseases Unit of a district hospital without a Nuclear Medicine service. Methods and material. A retrospective, descriptive study was conducted in 104 patients with nonadvanced breast cancer. The day before surgery, the patients underwent lymph node mammography in the referral hospital. The self-evaluation clinical guideline of the Spanish Society of Senology and Breast Pathology was used as part of the management protocol. We studied the efficacy of sentinel lymph node detection, the sensitivity of the procedure, and the mean number of axillary sentinel lymph nodes isolated per patient. Both the overall results obtained by the Breast Diseases Unit and the results obtained individually by each of the 3 surgeons working in the unit were evaluated. Results. The 3 main criteria of the self-evaluation guideline were fulfilled, namely: sentinel lymph node detection in 94.2%, the sensitivity ratio in 93.2% and the mean number of sentinel lymph nodes removed, 1.66 ± 0.84. These criteria were also fulfilled by each of the 3 surgeons working in the unit. The score of the self-assessment guideline was 33 out of 71 points, with level ii being the most prevalent level of quality. Conclusions. In our unit, application of the guidelines published by the Spanish Society of Senology and Breast Pathology to evaluate essential and basic aspects of selective sentinel lymph node biopsy in breast cancer demonstrated that quality criteria are being met in our unit, and allowed us to promote quality improvements (AU)